Charmacy Pharmaceutical Co., Ltd. Class H (HK:2289)
:2289
Top Page
Charmacy Pharmaceutical Co., Ltd. Class H
(2289)
Select Model
Select Model
Rating:60Neutral
Price Target:
HK$6.00
▼(-17.92% Downside)
Action:N/ADate:01/04/26
The score is primarily held back by financial fundamentals—especially high leverage and thin margins—despite a 2024 cash flow rebound. Technicals are supportive with a clear uptrend, but overbought signals add near-term risk. Valuation is helped by a moderate P/E and a high dividend yield.
Charmacy Pharmaceutical Co., Ltd. Class H (2289) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$627.48M
Dividend Yield8.03%
Average Volume (3M)283.00
Price to Earnings (P/E)8.0
Beta (1Y)0.35
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees847
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.25
Shares Outstanding108,000,000
10 Day Avg. Volume100
30 Day Avg. Volume283
Financial Highlights & Ratios
PEG Ratio8.95
Price to Book (P/B)1.61
Price to Sales (P/S)0.22
P/FCF Ratio11.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Charmacy Pharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Charmacy Pharmaceutical Co., Ltd. engages in the trading of pharmaceutical products in the People's Republic of China. The company offers western medicines, Chinese patent medicines, healthcare products, and related consulting services to downstre...
How the Company Makes Money
Revenue is generated primarily from selling pharmaceutical products. Specific, source-verifiable details on the company’s revenue mix (e.g., breakdown by product categories, distribution channels, geographies, or business segments), pricing model,...
Charmacy Pharmaceutical Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
44
Neutral
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.24B | 4.44B | 4.40B | 4.18B | 3.79B | 3.99B |
| Gross Profit | 320.54M | 324.76M | 292.74M | 268.61M | 234.12M | 237.40M |
| EBITDA | 153.32M | 155.71M | 136.92M | 121.03M | 107.55M | 111.03M |
| Net Income | 48.28M | 53.28M | 51.34M | 90.47M | 23.15M | 40.56M |
Balance Sheet | ||||||
| Total Assets | 3.49B | 3.46B | 3.25B | 2.87B | 2.76B | 2.80B |
| Cash, Cash Equivalents and Short-Term Investments | 509.97M | 563.15M | 644.76M | 503.81M | 641.76M | 602.02M |
| Total Debt | 1.05B | 1.70B | 1.37B | 1.19B | 1.33B | 1.25B |
| Total Liabilities | 2.90B | 2.84B | 2.65B | 2.27B | 2.26B | 2.30B |
| Stockholders Equity | 591.83M | 618.69M | 597.81M | 594.48M | 504.10M | 502.55M |
Cash Flow | ||||||
| Free Cash Flow | 274.87M | 90.31M | -137.39M | 35.46M | -44.58M | 79.10M |
| Operating Cash Flow | 280.72M | 106.04M | -96.54M | 44.05M | -19.54M | 131.08M |
| Investing Cash Flow | -5.82M | -15.64M | 39.34M | 71.76M | -24.40M | -54.78M |
| Financing Cash Flow | -233.69M | -31.54M | 101.26M | -191.21M | 74.40M | -2.68M |
Charmacy Pharmaceutical Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.36B | 19.61 | 6.83% | 2.72% | 29.81% | 10.40% | |
66 Neutral | HK$1.82B | 20.84 | 4.85% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$627.48M | 7.99 | 7.98% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$463.27M | -0.61 | -66.54% | ― | -43.86% | -217.25% |
* Healthcare Sector Average
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.81
-1.31
-18.40%
SHPMF
Shanghai Pharmaceuticals Holding Co
1.53
0.09
6.27%
SHTDF
Sinopharm Group Co
2.65
0.59
28.83%
HK:9955
ClouDr Group Limited
0.72
-0.25
-25.77%
HK:1931
IVD Medical Holding Limited
1.12
-0.58
-34.12%
HK:2192
Medlive Technology Co., Ltd.
8.61
-0.89
-9.37%
Charmacy Pharmaceutical Co., Ltd. Class H Corporate Events
Charmacy Pharmaceutical Sets Board Meeting to Approve 2025 Results and Consider Final Dividend
Mar 16, 2026
Charmacy Pharmaceutical Co., Ltd. has scheduled a board meeting for 27 March 2026 to review and approve the annual results of the company and its subsidiaries for the year ended 31 December 2025, along with their planned public release. The board ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.